Intuitive Surgical (NASDAQ:ISRG) stock is up in after-hours trading after reporting solid Q1-2024 results. The Robotic-assisted surgery systems company’s revenue grew to $1.89 billion, an 11% increase from $1.7 billion in the previous year and beating estimates of $1.87 billion. This growth was driven by a 16% rise in procedures (14.5% growth was expected) using its da Vinci surgical systems. Furthermore, earnings per share (EPS) of $1.50 beat the $1.42 consensus estimate and came in 22% higher than last year’s EPS of $1.23.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
What’s also worth noting is that during the quarter, Intuitive introduced new surgical systems, including the FDA-approved da Vinci 5, which represents the latest advancement in its technology lineup.
Is ISRG Stock a Buy, According to Analysts?
On TipRanks, ISRG stock comes in as a Moderate Buy based on 13 Buys, six Holds, and no Sell ratings assigned in the past three months. The average ISRG stock price target of $423.67 implies 13.7% upside potential.
